Neurodevelopmental outcome after COX inhibitor treatment for patent ductus arteriosus

Early Human Development

Volumn 86, Issue 2, 2010, Pages 87-92

  Rheinlaender, C ^a   Helfenstein, D ^a   Pees, C ^a   Walch, E ^a   Czernik, C ^a   Obladen, M ^a   Koehne, P ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bayley II scales; Griffiths scales; Ibuprofen; Indomethacin; Ligation; Neurodevelopmental outcome; Patent ductus arteriosus; Premature infants; Very low birth weight infants

Indexed keywords

IBUPROFEN; INDOMETACIN; PROSTAGLANDIN SYNTHASE INHIBITOR;

ARTICLE; BRAIN VENTRICLE HEMORRHAGE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GESTATIONAL AGE; HEART HEMODYNAMICS; HUMAN; INFANT; INFANT MORTALITY; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; NERVOUS SYSTEM DEVELOPMENT; PATENT DUCTUS ARTERIOSUS; RESPIRATORY DISTRESS; RETROSPECTIVE STUDY; VERY LOW BIRTH WEIGHT;

CENTRAL NERVOUS SYSTEM; CHILD DEVELOPMENT; CHILD, PRESCHOOL; CYCLOOXYGENASE INHIBITORS; DUCTUS ARTERIOSUS, PATENT; FEMALE; GESTATIONAL AGE; HUMANS; IBUPROFEN; INDOMETHACIN; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, VERY LOW BIRTH WEIGHT; MALE; PSYCHOMOTOR PERFORMANCE; RETROSPECTIVE STUDIES;

EID: 77649179288     PISSN: 03783782     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2009.12.009     Document Type: Article

References (29)

1. Fowlie P.W., and Davis P.G. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 3 (2002) CD000174
2. Kabra N.S., Schmidt B., Roberts R.S., Doyle L.W., Papile L., Fanaroff A., et al. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr 150 (2007) 229-234
3. Chorne N., Leonard C., Piecuch R., and Clyman R.I. Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics 119 (2007) 1165-1174
4. Van Overmeire B., and Chemtob S. The pharmacologic closure of the patent ductus arteriosus. Semin Fetal Neonatal Med 10 (2005) 177-184
5. Couser R.J., Hoekstra R.E., Ferrara T.B., Wright G.B., Cabalka A.K., and Connett J.E. Neurodevelopmental follow-up at 36 months' corrected age of preterm infants treated with prophylactic indomethacin. Arch Pediatr Adolesc Med 154 6 (2000) 598-602
6. Aranda J.V., and Thomas R. Systematic review: intravenous Ibuprofen in preterm newborns. Semin Perinatol 30 (2006) 114-120
7. Thomas R.L., Parker G.C., Van Overmeire B., and Aranda J.V. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr 164 (2005) 135-140
8. Safety Survey Report Named Patient Use of Ibuprofen Orphan Europe (PEDEA) Raport IBU/SURVEY/April 2003.
9. Lago P., Bettiol T., Salvadori S., Pitassi I., Vianello A., Chiandetti L., et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. Eur J Pediatr 161 (2002) 202-207
10. Morgan A.M., and Aldag J.C. Early identification of cerebral palsy using a profile of abnormal motor patterns. Pediatrics 98 4 Pt 1 (1996) 692-697
11. Brandt I, Sticker E. Griffith Entwicklungsskalen (GES) zur Beurteilung der Entwicklung in den ersten beiden Lebensjahren. 2. erweiterte und überarbeitete Version. Göttingen: Beltz Test-GmbH; 2001.
12. Bayley N. Bayley scales of infant development (Bsid-II). 3rd ed. (1999), Pearson Psychcorp, Sydney
13. Jobe A.H., and Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 163 (2001) 1723-1729
14. Ehrenkranz R.A., Walsh M.C., Vohr B.R., Jobe A.H., Wright L.L., Fanaroff A.A., et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 116 (2005) 1353-1360
15. The International Committee for the Classification of the Late Stages of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. II. The classification of retinal detachment. Arch Ophthalmol 105 (1987) 906-912
16. Papile L.A., Burstein J., Burstein R., and Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 92 (1978) 529-534
17. Resch B., Vollaard E., Maurer U., Haas J., Rosegger H., and Müller W. Risk factors and determinants of neurodevelopmental outcome in cystic periventricular leucomalacia. Eur J Pediatr 159 (2000) 663-670
18. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Surveillance of Cerebral Palsy in Europe (SCPE). Dev Med Child Neurol 42 12 (2000) 816-824
19. Koehne P.S., Bein G., Alexi-Meskhishvili V., Wenig Y., Bührer C., and Obladen M. Patent ductus arteriosus in very low birthweight infants: complications of pharmacological and surgical treatment. J Perinat Med 29 (2001) 327-334
20. Ramsay M., and Fitzhardinge P.M. A comparative study of two developmental scales: the Bayley and the Griffiths. Early Hum Dev 1 2 (1977) 151-157
21. Beail N. A comparative study of profoundly multiply handicapped children's scores on the Bayleys and Griffiths developmental scales. Child Care Health Dev 11 (1985) 31-36
22. Noori S., McCoy M., Friedlich P., Bright B., Gottipati V., Seri I., et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics 123 (2009) e138-e144
23. Sperandio M., Beedgen B., Feneberg R., Huppertz C., Brüssau J., Pöschl J., et al. Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation. Pediatrics 116 (2005) 1361-1366
24. Jegatheesan P., Ianus V., Buchh B., Yoon G., Chorne N., Ewig A., et al. Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: a multicenter, randomized, controlled trial. J Pediatr 153 (2008) 183-189
25. Hirt D., Van Overmeire B., Treluyer J.M., Langhendries J.P., Marguglio A., Eisinger M.J., et al. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. Br J Clin Pharmacol 65 (2008) 629-636
26. Buhrer C., Grimmer I., Metze B., and Obladen M. The CRIB (Clinical Risk Index for Babies) score and neurodevelopmental impairment at one year corrected age in very low birth weight infants. Intensive Care Med 26 3 (2000) 325-329
27. Brooks J.M., Travadi J.N., Patole S.K., Doherty D.A., and Simmer K. Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management. Arch Dis Child Fetal Neonatal Ed 90 (2005) F235-F239
28. Ohlsson A., Walia R., and Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 1 (2008) CD003481
29. Rheinlaender C., Helfenstein D., Walch E., Berns M., Obladen M., and Koehne P. Total serum bilirubin levels during cyclooxygenase inhibitor treatment for patent ductus arteriosus in preterm infants. Acta Paediatr 98 (2009) 36-42